Orcrist Bio Inc.

Calgary, Alberta, November 11, 2008 – Orcrist Bio Inc. announced today that the U.S. Patent and Trademark Office has approved the issuance of  a patent relating to the company's ORC-HYC750 drug candidate for the treatment of chemotherapy-related blood cell depletion and other underserved clinical indications.

The patent, entitled "Methods for Cell Mobilization Using In Vivo Treatment with Hyaluronan (HA)“, describes the use of various fragments of hyaluronic acid  to induce mobilization of stem cells, and provide a general increase in immune responsiveness through augmenting levels of certain circulating  cells of the immune system.  The patent provides an additional layer of protection to the technology acquired by Orcrist  under an exclusive license agreement with the University of Alberta, and also extends the life of this promising technology.

Orcrist is preparing to embark on a Phase I clinical study for ORC-HYC750 in early 2009.

For further information, please see the article on StemCellPatents.com.

About Orcrist Bio. Inc.

Orcrist Bio Inc. is a biotechnology company dedicated to developing and commercializing promising therapeutics for areas in which a clear market opportunity exists. Orcrist’s lead program revolves around HYC750, a novel stem cell mobilizer compound that promotes the egress of stem cells and other blood cells from the bone marrow into the blood, from which they can be harvested and applied toward treating chemotherapy-related white blood cell depletion. Orcrist is actively looking to add to its pipeline exploring the innate properties of HYC750 and its effects on stem cells, as well as through in-licensing opportunities of other products with clear market potential. Orcrist is located in Calgary, Alberta. The company is financed by its founders and by private investors. ( http://www.orcristbio.com ).